Hematologic Malignancy
Diffuse Large B-Cell Lymphoma
CI-CAN-00005107DLBCLExplore in graph →
Hematologic355 active trials5 approved drugs19 evidence items
- NCIt
- C8851
- DOID
- 0050745
- Other
- 4 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005107DLBCLExplore in graph →
Clinical trials
1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05952024 | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL(ACRUE) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT06649812 | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 |
| NCT03223610 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT05600686 | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 2 | 24 | University of California, DavisOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03349450 | DPX-Survivac and Checkpoint Inhibitor in DLBCL(SPiReL) | completed | Phase 2 | 25 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05139017 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | recruiting | Phase 2 / Phase 3 | 290 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT05907759 | Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03015896 | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 36 | David Bond, MDOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03463057 | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL(HO151DLBCL) | active not recruiting | Phase 2 | 109 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Sep 23, 2026 | clinicaltrials |
| NCT03628612 | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells | enrolling by invitation | Phase 2 | 500 | Autolus LimitedINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT04594798 | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | active not recruiting | Phase 2 | 39 | University of RochesterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05025800 | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT04002947 | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05757219 | Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | recruiting | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 204 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma | suspended | Phase 1 / Phase 2 | 33 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814001 | Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy(BiFAST) | not yet recruiting | Phase 2 | 55 | The Lymphoma Academic Research OrganisationOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma(EPCORE™ NHL-1) | active not recruiting | Phase 1 / Phase 2 | 666 | GenmabINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)(EPCORE™ NHL-3) | active not recruiting | Phase 1 / Phase 2 | 78 | GenmabINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04663347 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)(EPCORE™ NHL-2) | active not recruiting | Phase 1 / Phase 2 | 543 | GenmabINDUSTRY | 13 | Sep 9, 2026 | clinicaltrials |
| NCT04915248 | Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.(FIL_DALYA) | recruiting | Phase 2 | 28 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07502872 | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma(TPG) | not yet recruiting | Phase 2 | 30 | Brown UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06687772 | CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant(CNS-PHLAT) | recruiting | Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06784726 | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | recruiting | Phase 2 | 27 | University of WashingtonOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07365306 | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | City of Hope Medical CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02911142 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 70 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 38 | Yazeed SawalhaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06594939 | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 31 | Medical College of WisconsinOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | recruiting | Phase 1 / Phase 2 | 146 | BeiGeneINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 20 | Carrie Ho, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07724457 | Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 271 | National Cancer Institute (NCI)NIH | 0 | Aug 19, 2026 | clinicaltrials |
| NCT07774234 | Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 39 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03943901 | Split-Dose R-CHOP for Older Adults With DLBCL | active not recruiting | Phase 2 | 27 | University of Wisconsin, MadisonOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | not yet recruiting | Phase 1 / Phase 2 | 274 | Umoja BiopharmaINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT02889523 | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy(Epi-RCHOP) | active not recruiting | Phase 1 / Phase 2 | 214 | The Lymphoma Academic Research OrganisationOTHER | 2 | Aug 11, 2026 | clinicaltrials |
| NCT03136146 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06486051 | A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma(ENABLE-2) | recruiting | Phase 2 | 60 | Malaghan Institute of Medical ResearchOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | recruiting | Phase 1 / Phase 2 | 32 | Vironexis Biotherapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07712588 | Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) | not yet recruiting | Phase 2 / Phase 3 | 880 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | active not recruiting | Phase 2 / Phase 3 | 363 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06539195 | DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) | completed | Phase 2 | 59 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07069699 | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | recruiting | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
Data updated 2 hours agoSource updated Sep 29, 2026source: clinicaltrials